Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Liver symbols : Lly save search
Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - MediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer
Published: 2024-01-22 (Crawled : 22:00) - prnewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -0.51%
H: 0.37%
C: 0.32%
MDGL | $207.53 -6.63% 360K
|
Health Technology
|
| O: 1.29%
H: 0.35%
C: -3.04%
HEPA | $2.1118 17K
|
Health Technology
|
| O: -0.48%
H: 7.69%
C: 1.44%
ALT | $6.755 -1.96% 2M
|
Commercial Services
|
| O: -0.8%
H: 6.02%
C: 0.6%
ALNY | News | $144.345 -0.56% 330K
|
Health Technology
|
| O: 0.46%
H: 3.04%
C: 2.67%
ETNB | $8.9 0.22% 280K
|
Health Technology
|
| O: 1.19%
H: 0.63%
C: -0.72%
liver disease companies key growth market
Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight
Published: 2023-07-12 (Crawled : 21:00) - prnewswire.com
NVO | $122.69 -0.05% 3.8M
|
Health Technology
|
| O: 1.7%
H: 0.01%
C: -0.32%
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -0.08%
H: 0.46%
C: -1.26%
MDGL | $207.53 -6.63% 360K
|
Health Technology
|
| O: 0.41%
H: 3.34%
C: 1.43%
LPCN | $5.33 -2.02% 8.4K
|
Health Technology
|
| O: 0.11%
H: 2.15%
C: 1.02%
GALT | $3.25 -3.85% 120K
|
Health Technology
|
| O: 0.64%
H: 7.01%
C: 5.1%
ALNY | News | $144.345 -0.56% 330K
|
Health Technology
|
| O: 0.69%
H: 1.02%
C: 0.29%
AKRO | $20.525 0.07% 340K
|
Health Technology
|
| O: 0.78%
H: 1.1%
C: -0.15%
cirrhosis liver growth market
Insights on the Liver Disease Treatment Global Market to 2027 - by Treatment Type, Disease Type, End-user and Region
Published: 2022-04-12 (Crawled : 21:00) - prnewswire.com
GLAXF | $20.2 510
|
Health Technology
|
| O: 1.76%
H: 0.35%
C: 0.35%
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 0.15%
H: 0.0%
C: -4.71%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: -0.83%
ALPMY | $9.47 520K
|
Manufacturing
|
| O: 2.3%
H: 0.55%
C: 0.36%
VTRS | $11.21 0.81% 2.4M
|
Health Technology
|
| O: 0.37%
H: 2.99%
C: 2.61%
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: -0.2%
H: 1.83%
C: 1.83%
NVS | $94.285 1.85% 1.6M
|
Health Technology
|
| O: 0.12%
H: 0.44%
C: 0.17%
GSK | $39.585 0.8% 1.1M
|
Health Technology
|
| O: -0.24%
H: 0.45%
C: 0.39%
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -0.26%
H: 0.33%
C: -1.5%
BMY | $48.89 1.22% 5.1M
|
Health Technology
|
| O: 0.24%
H: 0.53%
C: 0.18%
ABBV | News | $165.97 0.8% 3.1M
|
Health Technology
|
| O: -1.38%
H: 0.0%
C: -3.67%
ABT | News | $106.76 1.42% 3.8M
|
Health Technology
|
| O: -0.7%
H: 1.91%
C: 1.63%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 0.77%
H: 0.0%
C: 0.0%
treatment liver disease market
Insulin Delivery Devices Market to Hit $39,371.8 Million Revenue by 2030, says P&S Intelligence
Published: 2022-03-18 (Crawled : 07:00) - prnewswire.com
NVO | $122.69 -0.05% 3.8M
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
MDT | $79.255 0.08% 2.6M
|
Health Technology
|
| O: 2.46%
H: 0.6%
C: 0.41%
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.12%
H: 1.93%
C: 0.63%
BDX | $234.09 0.4% 620K
|
Health Technology
|
| O: 0.68%
H: 0.55%
C: 0.24%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: -0.62%
H: 1.07%
C: 0.89%
PODD | $164.07 -0.4% 310K
|
Health Technology
|
| O: -0.35%
H: 5.54%
C: 5.11%
device liver intel insulin
Worldwide Drug Delivery Industry to 2027 - Growing Focus Towards Home Care and Self-Administration Presents Opportunities
Published: 2022-02-23 (Crawled : 18:00) - prnewswire.com
GNMSF | $290.38 220
|
Health Technology
|
| O: 5.23%
H: 0.0%
C: -0.34%
GLAXF | $20.2 510
|
Health Technology
|
| O: -0.48%
H: 3.79%
C: 3.12%
AZNCF | $138.24 800
|
Health Technology
|
| O: 1.68%
H: 0.0%
C: -1.1%
WST | $374.43 -0.77% 160K
|
Health Technology
|
| O: 0.24%
H: 0.24%
C: -3.38%
NVS | $94.285 1.85% 1.6M
|
Health Technology
|
| O: 1.82%
H: 0.07%
C: -1.0%
MDT | $79.255 0.08% 2.6M
|
Health Technology
|
| O: 0.5%
H: 0.25%
C: -1.16%
JNJ | News | $147.895 1.48% 5.8M
|
Health Technology
|
| O: 0.23%
H: 0.7%
C: -0.18%
GSK | $39.585 0.8% 1.1M
|
Health Technology
|
| O: 1.9%
H: 0.07%
C: -0.87%
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.59%
H: 0.89%
C: -0.93%
BDX | $234.09 0.4% 620K
|
Health Technology
|
| O: 0.22%
H: 1.9%
C: 1.48%
ABBV | News | $165.97 0.8% 3.1M
|
Health Technology
|
| O: 0.45%
H: 1.46%
C: 0.37%
MMM | $92.09 0.67% 1.5M
|
Producer Manufacturing
|
| O: 0.0%
H: 0.4%
C: -1.61%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 2.09%
H: 0.08%
C: -1.22%
GMAB | $28.68 1.23% 150K
|
Health Technology
|
| O: 1.06%
H: 0.0%
C: -1.67%
AZN | $68.41 0.07% 2.9M
|
Health Technology
|
| O: 1.43%
H: 0.0%
C: -1.85%
ATRS | $5.59 0.0%
|
Health Technology
|
| O: 0.29%
H: 0.87%
C: -2.6%
AMGN | $267.41 1.77% 1.4M
|
Health Technology
|
| O: 0.57%
H: 0.48%
C: -0.75%
drug liver growing drug delivery
At 9.7% CAGR, Insulin Delivery Devices Market Size to hit USD 33.05 Billion in 2028, Says Brandessence Market Research
Published: 2022-01-03 (Crawled : 12:00) - prnewswire.com
NVO | $122.69 -0.05% 3.8M
|
Health Technology
|
| O: -2.14%
H: 0.0%
C: 0.0%
MDT | $79.255 0.08% 2.6M
|
Health Technology
|
| O: -0.14%
H: 0.0%
C: 0.0%
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -0.78%
H: 0.0%
C: 0.0%
BDX | $234.09 0.4% 620K
|
Health Technology
|
| O: -0.43%
H: 0.0%
C: 0.0%
PODD | $164.07 -0.4% 310K
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
ce mark device research liver insulin
Global $19 Billion Home-Use Insulin Delivery Devices Markets, 2015-2020 & 2021-2030
Published: 2021-12-20 (Crawled : 19:00) - prnewswire.com
NVO | $122.69 -0.05% 3.8M
|
Health Technology
|
| O: 1.2%
H: 1.62%
C: 1.37%
MDT | $79.255 0.08% 2.6M
|
Health Technology
|
| O: 0.45%
H: 2.78%
C: 1.68%
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.2%
H: 0.74%
C: 0.33%
BDX | $234.09 0.4% 620K
|
Health Technology
|
| O: 0.57%
H: 0.63%
C: -0.8%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 0.76%
H: 0.67%
C: 0.45%
PODD | $164.07 -0.4% 310K
|
Health Technology
|
| O: 0.29%
H: 3.22%
C: 3.08%
device liver insulin
Transdermal Drug Delivery Market is Growing at a CAGR of 9.8% during the Study Period from 2021 to 2026, Asserts DelveInsight
Published: 2021-12-14 (Crawled : 17:00) - prnewswire.com
TRUMF | $16.928 1.9K
|
Health Technology
|
| O: -1.42%
H: 0.02%
C: 0.02%
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -3.62%
H: 0.0%
C: -0.56%
AZNCF | $138.24 800
|
Health Technology
|
| O: -1.44%
H: 5.82%
C: 1.91%
TRUMY | $16.507 34K
|
Manufacturing
|
| O: -1.37%
H: 0.68%
C: 0.37%
NVO | $122.69 -0.05% 3.8M
|
Health Technology
|
| O: -1.8%
H: 0.08%
C: -0.43%
MDT | $79.255 0.08% 2.6M
|
Health Technology
|
| O: -0.2%
H: 0.66%
C: -0.52%
JNJ | News | $147.895 1.48% 5.8M
|
Health Technology
|
| O: 1.9%
H: 0.0%
C: 0.0%
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.82%
H: 0.92%
C: 0.66%
BMY | $48.89 1.22% 5.1M
|
Health Technology
|
| O: 2.71%
H: 2.77%
C: 1.21%
BDX | $234.09 0.4% 620K
|
Health Technology
|
| O: -0.3%
H: 0.1%
C: -1.63%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
PODD | $164.07 -0.4% 310K
|
Health Technology
|
| O: -0.82%
H: 0.38%
C: -2.71%
ENDP | $0.2926 -9.6%
|
Health Technology
|
| O: -5.76%
H: 7.53%
C: 0.47%
AZN | $68.41 0.07% 2.9M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
ATRS | $5.59 0.0%
|
Health Technology
|
| O: -0.31%
H: 0.7%
C: -0.63%
drug liver growing drug delivery
Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021
Published: 2021-11-12 (Crawled : 14:00) - biospace.com/
NVO | $122.69 -0.05% 3.8M
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
ALNY | News | $144.345 -0.56% 330K
|
Health Technology
|
| O: -2.06%
H: 0.0%
C: 0.0%
disease liver disease phase 1 liver trial
Lilly's tirzepatide led to greater improvements in liver fat content compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 MRI sub-study
Published: 2021-09-30 (Crawled : 10:00) - biospace.com/
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 1.05%
H: 1.88%
C: -0.74%
diabetes insulin liver tirzepatide
Life Sciences and Healthcare Industry Leaders Invest in Tact.ai to Deliver Next Generation Customer Engagement
Published: 2021-09-20 (Crawled : 21:00) - prnewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 2.04%
H: 0.72%
C: -0.81%
life science liver
Home-Use Insulin Delivery Devices Market to Hit $19,087.6 Million Revenue by 2030 says P&S Intelligence
Published: 2021-08-18 (Crawled : 08:00) - prnewswire.com
NVO | $122.69 -0.05% 3.8M
|
Health Technology
|
| O: 0.04%
H: 0.72%
C: -0.91%
MDT | $79.255 0.08% 2.6M
|
Health Technology
|
| O: 0.03%
H: 0.28%
C: -1.12%
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -0.26%
H: 1.01%
C: -1.28%
BDX | $234.09 0.4% 620K
|
Health Technology
|
| O: 0.07%
H: 0.3%
C: -2.11%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 0.17%
H: 1.16%
C: -0.04%
PODD | $164.07 -0.4% 310K
|
Health Technology
|
| O: 0.21%
H: 0.12%
C: -2.14%
insulin device liver
CORRECTING and REPLACING - GoodRx and Boehringer Ingelheim Announce Joint Effort to Deliver Affordability Solutions to Patients
Published: 2021-08-09 (Crawled : 22:00) - globenewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -0.15%
H: 1.62%
C: 1.01%
GDRX 4 | $6.675 -0.82% 280K
|
Technology Services
|
| O: 0.29%
H: 0.67%
C: -1.46%
ford liver
GoodRx and Boehringer Ingelheim Announce Joint Effort to Deliver Affordability Solutions to PatientsPotential to provide approximately $15 million a year in savings for life-enhancing medications
Published: 2021-08-09 (Crawled : 21:00) - biospace.com/
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.33%
H: 3.2%
C: 0.98%
GDRX 4 | $6.675 -0.82% 280K
|
Technology Services
|
| O: -1.34%
H: 1.08%
C: -0.35%
ford potential liver
GoodRx and Boehringer Ingelheim Announce Joint Effort to Deliver Affordability Solutions to Patients
Published: 2021-08-09 (Crawled : 13:15) - globenewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.33%
H: 3.2%
C: 0.98%
GDRX 4 | $6.675 -0.82% 280K
|
Technology Services
|
| O: -1.34%
H: 1.08%
C: -0.35%
ford liver
Lilly Delivers Strong Second-Quarter 2021 Financial Results, Updates 2021 Financial Guidance
Published: 2021-08-03 (Crawled : 12:00) - biospace.com/
ABCL | $3.82 -2.3% 620K
|
|
| O: 1.14%
H: 0.0%
C: -1.56%
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -0.75%
H: 5.97%
C: 4.59%
RIGL | $1.035 -1.43% 430K
|
Health Technology
|
| O: 0.5%
H: 0.5%
C: -6.44%
DTIL | $9.86 -8.02% 140K
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: -1.21%
MRUS | $39.8 -1.66% 470K
|
Health Technology
|
| O: 0.9%
H: 1.45%
C: 0.67%
financial results results liver
Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2021-07-21 (Crawled : 13:00) - biospace.com/
NVO | $122.69 -0.05% 3.8M
|
Health Technology
|
| O: 0.9%
H: 0.72%
C: 0.58%
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.58%
H: 0.42%
C: 0.38%
ALNY | News | $144.345 -0.56% 330K
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: -2.13%
disease liver disease treatment phase 1 results liver trial phase 2 phase 3
Dicerna Initiates Patient Dosing in ESTRELLA Phase 2 Clinical Trial of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2021-06-22 (Crawled : 12:15) - biospace.com/
NVO | $122.69 -0.05% 3.8M
|
Health Technology
|
| O: -0.39%
H: 0.27%
C: -0.21%
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -0.02%
H: 0.44%
C: -0.53%
ALNY | News | $144.345 -0.56% 330K
|
Health Technology
|
| O: 0.08%
H: 1.01%
C: 0.9%
disease liver disease treatment phase 2 liver trial
Lilly Delivers First-Quarter 2021 Financial Results, Adjusts 2021 Financial Guidance
Published: 2021-04-27 (Crawled : 12:00) - biospace.com/
GSK | $39.585 0.8% 1.1M
|
Health Technology
|
| O: -0.03%
H: 0.26%
C: -0.11%
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -1.72%
H: 1.02%
C: -0.97%
VIR | $7.775 -2.32% 510K
|
Health Technology
|
| O: 0.0%
H: 0.16%
C: -3.69%
RIGL | $1.035 -1.43% 430K
|
Health Technology
|
| O: 1.54%
H: 0.25%
C: -3.28%
DTIL | $9.86 -8.02% 140K
|
Health Technology
|
| O: 0.4%
H: 3.33%
C: -1.11%
MRUS | $39.8 -1.66% 470K
|
Health Technology
|
| O: -0.64%
H: 0.0%
C: -2.8%
financial results results liver
Gainers vs Losers
| 70% | 30% |
Top 10 Gainers
AGBA | News | $1.305 226.25% 130M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
NVFY | $2.65 25.59% 33M
|
Consumer Durables
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.